Header Logo

Jonathan Kay MD

TitleProfessor
Endowed TitleTimothy S. and Elaine L. Peterson Chair in Rheumatology
InstitutionUMass Chan Medical School
DepartmentMedicine
AddressUMass Memorial Medical Center
119 Belmont Street
Worcester MA 01605
Phone508-334-6273
vCardDownload vCard
    Other Positions
    InstitutionT.H. Chan School of Medicine
    DepartmentMedicine
    DivisionRheumatology

    InstitutionT.H. Chan School of Medicine
    DepartmentPopulation and Quantitative Health Sciences

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentClinical Population Health Research

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentImmunology and Microbiology Program

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentMasters in Clinical Investigation

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentMD/PhD Program


    Collapse Biography 
    Collapse education and training
    Harvard University, Cambridge, MA, United StatesABBioChemical Sciences
    University of California, San Francisco, San Francisco, CA, United StatesMD

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shridharmurthy D, Lapane KL, Khan S, Yi E, Baek J, Kay J, Liu SH. Development and test-retest reliability of a screening tool for axial spondyloarthritis. PLoS One. 2022; 17(7):e0269494. PMID: 35802613.
      Citations:    Fields:    Translation:Humans
    2. Furst DE, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Kim SH, Bae YJ, Yang GE, Yoo JK, Kay J, Keystone E. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology (Oxford). 2022 04 11; 61(4):1385-1395. PMID: 34142111.
      Citations: 2     Fields:    Translation:Humans
    3. Shridharmurthy D, Khan S, Lapane KL, Yi E, Kay J, Liu SH. Development of a screening tool to identify patients with axial spondyloarthritis: a cognitive interview study. Clin Rheumatol. 2022 May; 41(5):1391-1402. PMID: 35059882.
      Citations: 1     Fields:    Translation:Humans
    4. Khan S, Shridharmurthy D, Lapane KL, Dube C, Kay J, Yi E, Liu SH. The disease burden of axial spondyloarthritis: through a gendered lens. Clin Rheumatol. 2022 Apr; 41(4):1115-1124. PMID: 34988682.
      Citations:    Fields:    Translation:Humans
    5. Lapane KL, Dubé C, Ferrucci K, Khan S, Kuhn KA, Yi E, Kay J, Liu SH. Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study. BMC Fam Pract. 2021 12 20; 22(1):251. PMID: 34930136.
      Citations:    Fields:    Translation:Humans
    6. Dube CE, Lapane KL, Ferrucci KA, Beccia AL, Khan SK, Yi E, Kay J, Kuhn KA, Ogdie A, Liu SH. Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. Rheumatol Ther. 2021 Jun; 8(2):1015-1030. PMID: 34059989.
      Citations:    
    7. Lapane KL, Shridharmurthy D, Khan S, Lindstrom D, Beccia A, Yi E, Kay J, Dube C, Liu SH. Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study. PLoS One. 2021; 16(5):e0252018. PMID: 34029339.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    8. Davidson A, Brimhall D, Kay J, Keystone E, Lee SJ, Kim SH, Bae YJ, Choi EJ, Furst DE. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40?mg/0.4?mL) by autoinjector and prefilled syringe in healthy subjects. Br J Clin Pharmacol. 2021 11; 87(11):4323-4333. PMID: 33822406.
      Citations: 2     Fields:    Translation:Humans
    9. Yu KS, Jang IJ, Lim HS, Hong JH, Kim MG, Park MK, Cho DY, Park MS, Chung JY, Ghim JL, Lee S, Yoon SK, Kwon IS, Lee SJ, Kim SH, Bae YJ, Cha JB, Furst DE, Keystone E, Kay J. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clin Transl Sci. 2021 07; 14(4):1280-1291. PMID: 33503313.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    10. Kay J, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Bae YJ, Yang GE, Yoo JK, Furst DE, Keystone E. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther. 2021 02 05; 23(1):51. PMID: 33546755.
      Citations: 4     Fields:    Translation:Humans
    11. Shridharmurthy D, Zhao D, Lapane KL, Baek J, Kay J, Liu SH. Disease Burden and Health-Related Quality of Life Among Women and Men with Spondyloarthritis: An Exploratory Analysis of a Population-Based Sample. J Womens Health (Larchmt). 2021 11; 30(11):1637-1644. PMID: 33450162.
      Citations:    Fields:    Translation:Humans
    12. Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 06; 80(6):727-738. PMID: 33452004.
      Citations: 12     Fields:    Translation:HumansAnimalsCTClinical Trials
    13. Liu SH, Shridharmurthy D, Lapane KL, Dubé CE, Gravallese EM, Kay J. Physical Activity and Attitudes Toward Exercise in People With Axial and Peripheral Spondyloarthritis. J Rheumatol. 2021 04; 48(4):513-519. PMID: 33060306.
      Citations:    Fields:    Translation:Humans
    14. Kay J, Harigai M, Rancourt J, Dickson C, Melby T, Issa M, de la Torre I, Isaka Y, Cardoso A, Saifan C, Keystone EC, van Vollenhoven RF, Giles JT, Huizinga TW, Kremer JM. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020 10; 6(3). PMID: 33028675.
      Citations:    
    15. Lapane KL, Khan S, Shridharmurthy D, Beccia A, Dubé C, Yi E, Kay J, Liu SH. Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study. BMC Fam Pract. 2020 09 29; 21(1):204. PMID: 32993510.
      Citations: 7     Fields:    Translation:Humans
    16. Joo W, Almario CV, Ishimori M, Park Y, Jusufagic A, Noah B, Gensler LS, Venuturupalli RS, Kay J, Weisman MH, Spiegel BMR. Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. ACR Open Rheumatol. 2020 Jul; 2(7):391-400. PMID: 32519467.
      Citations:    
    17. Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis Rheumatol. 2020 07; 72(7):1067-1071. PMID: 32253823.
      Citations: 1     Fields:    Translation:Humans
    18. Kay J. Overcoming barriers to biosimilars in inflammatory arthritis. Nat Rev Rheumatol. 2020 Feb; 16(2):65-66. PMID: 31873190.
      Citations: 1     Fields:    Translation:Humans
    19. Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019 12 12; 21(1):285. PMID: 31831064.
      Citations: 2     Fields:    Translation:Humans
    20. Liu SH, Morais SA, Lapane KL, Kay J. Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic review. Semin Arthritis Rheum. 2020 04; 50(2):289-302. PMID: 31839210.
      Citations: 3     Fields:    Translation:Humans
    21. Salomon-Escoto K, Kay J. The "Treat to Target" Approach to Rheumatoid Arthritis. Rheum Dis Clin North Am. 2019 11; 45(4):487-504. PMID: 31564292.
      Citations: 5     Fields:    Translation:Humans
    22. Kay J, Schwartzman S. Controversies in Rheumatology. Rheum Dis Clin North Am. 2019 08; 45(3):xv-xvi. PMID: 31277758.
      Citations:    Fields:    Translation:Humans
    23. Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 07; 71(7):1101-1111. PMID: 30848558.
      Citations: 28     Fields:    Translation:Humans
    24. Kay J. Are There Benefits and Risks to Biosimilars from a Patient Perspective? Rheum Dis Clin North Am. 2019 08; 45(3):465-476. PMID: 31277756.
      Citations: 2     Fields:    Translation:Humans
    25. Kay J. A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. J Intern Med. 2019 06; 285(6):693-695. PMID: 30990229.
      Citations:    Fields:    Translation:Humans
    26. Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Ann Rheum Dis. 2019 07; 78(7):872-878. PMID: 30712015.
      Citations: 8     Fields:    Translation:Humans
    27. Dzubur E, Khalil C, Almario CV, Noah B, Minhas D, Ishimori M, Arnold C, Park Y, Kay J, Weisman MH, Spiegel BMR. Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms. Arthritis Care Res (Hoboken). 2019 02; 71(2):323-330. PMID: 29781587.
      Citations: 6     Fields:    Translation:Humans
    28. Kay J, Dörner T, Emery P, Kvien TK, Breedveld FC. Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. Ann Rheum Dis. 2020 04; 79(4):e44. PMID: 30659047.
      Citations: 4     Fields:    
    29. Bridges SL, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol. 2018 03; 70(3):334-344. PMID: 29411547.
      Citations: 10     Fields:    Translation:Humans
    30. Gravallese EM, Kay J, Duryea J, Solomon DH. Reply. Arthritis Rheumatol. 2018 03; 70(3):476. PMID: 29193854.
      Citations:    Fields:    Translation:Humans
    31. Baecklund E, Backlin C, Rönnelid J, Toes R, Huizinga T, Åhlin E, Askling J, Hochberg FH, Klareskog L, Kay J, Smedby KE. Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scand J Rheumatol. 2018 07; 47(4):270-275. PMID: 29336646.
      Citations: 1     Fields:    Translation:Humans
    32. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 02; 77(2):165-174. PMID: 28866648.
      Citations: 61     Fields:    Translation:Humans
    33. Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clin Immunol. 2018 01; 186:87-93. PMID: 28811201.
      Citations: 15     Fields:    Translation:Humans
    34. Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA, Han R, Ball S, Coleman C, Lo E, Wohlfahrt A, Sury M, Yin M, Yu Z, Zak A, Gravallese EM. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2017 09; 69(9):1741-1750. PMID: 28544807.
      Citations: 12     Fields:    Translation:Humans
    35. Kay J, Winthrop KL. Pharmacotherapy: Biosimilar switching - "To set a form upon desired change". Nat Rev Rheumatol. 2017 07; 13(7):391-392. PMID: 28569266.
      Citations:    Fields:    
    36. Cohen S, Kay J. Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol. 2017 05; 29(3):260-268. PMID: 28306596.
      Citations: 7     Fields:    Translation:Humans
    37. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017 Jul; 76(7):1279-1284. PMID: 28389552.
      Citations: 31     Fields:    Translation:Humans
    38. Braun J, Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2017 Mar; 16(3):289-302. PMID: 28068848.
      Citations: 4     Fields:    Translation:Humans
    39. Goyal A, Linskey KR, Kay J, Duncan LM, Nazarian RM. Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders: Implications for Targeted Inhibition. Am J Clin Pathol. 2016 Dec; 146(6):709-717. PMID: 28077400.
      Citations: 3     Fields:    Translation:Humans
    40. Stavre Z, Upchurch K, Kay J, Gravallese EM. Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. Curr Rheumatol Rep. 2016 Dec; 18(12):72. PMID: 27812955.
      Citations: 6     Fields:    Translation:Humans
    41. Schaub S, Sirkis HM, Kay J. Imaging for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome. Rheum Dis Clin North Am. 2016 11; 42(4):695-710. PMID: 27742022.
      Citations: 8     Fields:    Translation:Humans
    42. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Rheumatol. 2016 12; 43(12):2120-2130. PMID: 27803138.
      Citations: 17     Fields:    Translation:Humans
    43. Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, Weisman M, Westhoff TH, Yamanaka H, Braun J. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017 04; 76(4):632-638. PMID: 27658678.
      Citations: 38     Fields:    Translation:Humans
    44. Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017 01; 76(1):4-6. PMID: 27566795.
      Citations: 8     Fields:    
    45. Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016 Jul-Aug; 34(4 Suppl 98):69-76. PMID: 27586809.
      Citations: 10     Fields:    Translation:HumansAnimals
    46. Kay J. Editorial: Biosimilars: New or Déjà Vu? Arthritis Rheumatol. 2016 05; 68(5):1049-52. PMID: 26748580.
      Citations: 3     Fields:    
    47. Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, Willers J, Kay J. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016 Apr; 54(4):315-22. PMID: 26952037.
      Citations: 4     Fields:    Translation:Humans
    48. Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016 06; 75(6):974-82. PMID: 26964144.
      Citations: 59     Fields:    Translation:Humans
    49. Duryea J, Russell R, Gravallese EM, Kay J, Han R, Lu B, Solomon DH. Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. Arthritis Rheumatol. 2016 Feb; 68(2):332-6. PMID: 26473501.
      Citations:    Fields:    Translation:Humans
    50. Deodhar A, Strand V, Kay J, Braun J. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016 May; 75(5):791-4. PMID: 26768406.
      Citations: 33     Fields:    Translation:Humans
    51. Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annu Rev Med. 2016; 67:273-91. PMID: 26768242.
      Citations: 14     Fields:    Translation:HumansAnimals
    52. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016 Jun; 75(6):1081-91. PMID: 26511996.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    53. Gvozdenovi? E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TW, Kay J, Martin Mola E, Moots RJ, da Silva JA, Smolen J, Veale D, Landewé RB. Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. J Clin Rheumatol. 2015 Oct; 21(7):349-54. PMID: 26398461.
      Citations: 3     Fields:    Translation:Humans
    54. Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015 Dec; 11(12):713-24. PMID: 26282080.
      Citations: 37     Fields:    Translation:Humans
    55. Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Int J Rheum Dis. 2016 Nov; 19(11):1143-1156. PMID: 26259617.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    56. Castañeda-Hernández G, González-Ramírez R, Kay J, Scheinberg MA. Biosimilars in rheumatology: what the clinician should know. RMD Open. 2015; 1(1):e000010. PMID: 26509046.
      Citations:    
    57. Navarro-Compán V, Smolen JS, Huizinga TW, Landewé R, Ferraccioli G, da Silva JA, Moots RJ, Kay J, van der Heijde D. Quality indicators in rheumatoid arthritis: results from the METEOR database. Rheumatology (Oxford). 2015 Sep; 54(9):1630-9. PMID: 25877910.
      Citations: 12     Fields:    Translation:Humans
    58. Smolen JS, Kay J, Doyle M, Landewé R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor ? inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015 Jan 22; 17:14. PMID: 25627338.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    59. Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1? production and peritoneal inflammation. Ann Rheum Dis. 2015 Nov; 74(11):2062-9. PMID: 24914072.
      Citations: 13     Fields:    Translation:AnimalsCells
    60. Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford). 2014 Sep; 53(9):1613-7. PMID: 24706993.
      Citations: 1     Fields:    Translation:Humans
    61. Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014 Jul; 69(7):661-8. PMID: 24582176.
      Citations: 24     Fields:    Translation:Humans
    62. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015 Jun; 74(6):1051-7. PMID: 24550171.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    63. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, Gravallese EM, Furst DE. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014 Feb 03; 16(1):R40. PMID: 24485007.
      Citations: 42     Fields:    Translation:Humans
    64. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015 Mar; 74(3):538-46. PMID: 24344160.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    65. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, El-Zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 Jan; 73(1):62-8. PMID: 24095940.
      Citations: 234     Fields:    Translation:Humans
    66. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013 Oct; 72(10):1589-93. PMID: 23897773.
      Citations: 14     Fields:    Translation:Humans
    67. Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014 Oct; 73(10):1811-8. PMID: 23897769.
      Citations: 12     Fields:    Translation:Humans
    68. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct; 52(10):1845-55. PMID: 23838027.
      Citations: 7     Fields:    Translation:Humans
    69. Kay J. Rheumatic rarities. Preface. Rheum Dis Clin North Am. 2013 May; 39(2):xv-xvi. PMID: 23597977.
      Citations:    Fields:    Translation:Humans
    70. Chopra R, Chaudhary N, Kay J. Relapsing polychondritis. Rheum Dis Clin North Am. 2013 May; 39(2):263-76. PMID: 23597963.
      Citations: 12     Fields:    Translation:Humans
    71. Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol. 2013 May; 35(3):351-6. PMID: 23051628.
      Citations: 1     Fields:    Translation:Humans
    72. Kay J, Gravallese EM. Rheumatoid arthritis: erosion defined: back to basics. Nat Rev Rheumatol. 2013 Jun; 9(6):323-4. PMID: 23609778.
      Citations:    Fields:    Translation:Humans
    73. Vital EM, Kay J, Emery P. Rituximab biosimilars. Expert Opin Biol Ther. 2013 Jul; 13(7):1049-62. PMID: 23600760.
      Citations: 19     Fields:    Translation:Humans
    74. Lima XT, Alora-Palli MB, Kimball AB, Kay J. Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):637-42. PMID: 23097320.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    75. Schneeberger D, Tyndall A, Kay J, Søndergaard KH, Carreira PE, Morgiel E, Deuschle K, Derk CT, Widuchowska M, Walker UA. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford). 2013 Mar; 52(3):560-7. PMID: 23221323.
      Citations: 6     Fields:    Translation:Humans
    76. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012 Dec; 51 Suppl 6:vi5-9. PMID: 23221588.
      Citations: 119     Fields:    Translation:Humans
    77. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012 Dec; 51 Suppl 6:vi28-36. PMID: 23221584.
      Citations: 59     Fields:    Translation:Humans
    78. Kay J, Feagan BG, Guirguis MS, Keystone EC, Klein AV, Lubiniecki AS, Mould DR, Nyarko KA, Ridgway AA, Trudeau ME, Wang J. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals. 2012 Nov; 40(6):517-27. PMID: 23084808.
      Citations: 4     Fields:    
    79. Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol. 2012 Aug; 26(4):489-503. PMID: 23040363.
      Citations: 17     Fields:    Translation:Humans
    80. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol. 2012 06 05; 8(7):430-6. PMID: 22664834.
      Citations: 30     Fields:    Translation:Humans
    81. Smolen JS, Kay J, Landewé RB, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Zhou Y, Hsia EC, Doyle MK. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012 Oct; 71(10):1671-9. PMID: 22459542.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    82. Bernstein EJ, Kay J, Gibofsky A. Erratum to: Treating rheumatoid arthritis to target: an international initiative. Curr Rev Musculoskelet Med. 2011 Sep; 4(3):157. PMID: 21728012.
      Citations:    
    83. Bernstein EJ, Kay J, Gibofsky A. Treating rheumatoid arthritis to target: an international initiative. Curr Rev Musculoskelet Med. 2011 09; 4(3):79-83. PMID: 21656282.
      Citations:    
    84. Salomon-Escoto KI, Gravallese EM, Kay J. Assessment of control of rheumatoid arthritis disease activity. Best Pract Res Clin Rheumatol. 2011 Aug; 25(4):497-507. PMID: 22137920.
      Citations: 8     Fields:    Translation:Humans
    85. Lin HW, Roberts DS, Kay J, Stankovic KM. Sensorineural hearing loss following imatinib (Gleevec) administration. Otolaryngol Head Neck Surg. 2012 Feb; 146(2):335-7. PMID: 21753034.
      Citations: 7     Fields:    Translation:Humans
    86. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011 Dec; 65(6):1095-1106.e7. PMID: 21724294.
      Citations: 36     Fields:    Translation:Humans
    87. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011 Jul; 260(1):105-11. PMID: 21586680.
      Citations: 47     Fields:    Translation:Humans
    88. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011 May 12; 13(3):112. PMID: 21586106.
      Citations: 18     Fields:    Translation:HumansAnimals
    89. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken). 2011 Apr; 63(4):512-21. PMID: 21452264.
      Citations: 29     Fields:    Translation:HumansAnimals
    90. Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol. 2011 Apr; 64(4):741-7. PMID: 21414498.
      Citations: 2     Fields:    Translation:Humans
    91. Kay J, Czirják L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis. 2010 Nov; 69(11):1895-7. PMID: 20959325.
      Citations: 4     Fields:    Translation:Humans
    92. Lebiedz-Odrobina D, Kay J. Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin North Am. 2010 Nov; 36(4):681-99. PMID: 21092846.
      Citations: 28     Fields:    Translation:Humans
    93. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Khanna D, Kvien TK, Laing T, Liao K, Mease P, Ménard HA, Moreland LW, Nair R, Pincus T, Ringold S, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep; 62(9):2582-91. PMID: 20872596.
      Citations: 90     Fields:    Translation:Humans
    94. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep; 69(9):1580-8. PMID: 20699241.
      Citations: 1071     Fields:    Translation:Humans
    95. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep; 62(9):2569-81. PMID: 20872595.
      Citations: 2389     Fields:    Translation:Humans
    96. Funovits J, Aletaha D, Bykerk V, Combe B, Dougados M, Emery P, Felson D, Hawker G, Hazes JM, Huizinga T, Kay J, Kvien TK, Smolen JS, Symmons D, Tak PP, Silman A. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis. 2010 Sep; 69(9):1589-95. PMID: 20699242.
      Citations: 39     Fields:    Translation:Humans
    97. Kay J, Rahman MU. Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid. 2010 Jun 15; 4:159-70. PMID: 20694072.
      Citations:    
    98. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am. 2010 May; 36(2):385-404. PMID: 20510240.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    99. Koreishi AF, Nazarian RM, Saenz AJ, Klepeis VE, McDonald AG, Farris AB, Colvin RB, Duncan LM, Mandal RV, Kay J. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med. 2009 Dec; 133(12):1943-8. PMID: 19961249.
      Citations: 8     Fields:    Translation:Humans
    100. Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging. 2009 Dec; 30(6):1335-40. PMID: 19937927.
      Citations: 7     Fields:    Translation:Humans
    101. Kroshinsky D, Kay J, Nazarian RM. Case records of the Massachusetts General Hospital. Case 37-2009. A 46-year-old woman with chronic renal failure, leg swelling, and skin changes. N Engl J Med. 2009 Nov 26; 361(22):2166-76. PMID: 19940302.
      Citations: 3     Fields:    Translation:Humans
    102. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009 Oct; 253(1):81-9. PMID: 19709997.
      Citations: 21     Fields:    Translation:Humans
    103. Kay J, Westhovens R. Methotrexate: the gold standard without standardisation. Ann Rheum Dis. 2009 Jul; 68(7):1081-2. PMID: 19525405.
      Citations: 4     Fields:    Translation:Humans
    104. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jul 18; 374(9685):210-21. PMID: 19560810.
      Citations: 166     Fields:    Translation:HumansCTClinical Trials
    105. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol. 2009 Jul; 36(7):1371-9. PMID: 19487269.
      Citations: 15     Fields:    Translation:Humans
    106. Collier DS, Grant RW, Estey G, Surrao D, Chueh HC, Kay J. Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. Arthritis Rheum. 2009 Apr 15; 61(4):495-500. PMID: 19333984.
      Citations: 7     Fields:    Translation:Humans
    107. Collier DS, Kay J, Estey G, Surrao D, Chueh HC, Grant RW. A rheumatology-specific informatics-based application with a disease activity calculator. Arthritis Rheum. 2009 Apr 15; 61(4):488-94. PMID: 19333976.
      Citations: 8     Fields:    Translation:Humans
    108. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis. 2008 Dec; 67 Suppl 3:iii66-9. PMID: 19022818.
      Citations: 12     Fields:    Translation:Humans
    109. Kay J. Nephrogenic systemic fibrosis: a new concern for rheumatologists. Nat Clin Pract Rheumatol. 2008 Sep; 4(9):445. PMID: 18756271.
      Citations:    Fields:    Translation:Humans
    110. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008 Aug; 58(8):2543-8. PMID: 18668587.
      Citations: 40     Fields:    Translation:Humans
    111. Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep. 2008 Jul; 10(3):195-204. PMID: 18638427.
      Citations: 6     Fields:    Translation:Humans
    112. Sarraf P, Kay J, Reginato AM. Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Curr Rheumatol Rep. 2008 Jul; 10(3):235-48. PMID: 18638433.
      Citations: 4     Fields:    Translation:HumansCells
    113. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008 Apr; 58(4):964-75. PMID: 18383539.
      Citations: 95     Fields:    Translation:Humans
    114. Kay J, Bazari H, Avery LL, Koreishi AF. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008 Feb 21; 358(8):827-38. PMID: 18287606.
      Citations: 14     Fields:    Translation:Humans
    115. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med. 2008 Feb; 75(2):112, 114, 117. PMID: 18290354.
      Citations: 4     Fields:    Translation:Humans
    116. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct; 56(10):3433-41. PMID: 17907148.
      Citations: 41     Fields:    Translation:Humans
    117. Cha JH, Furie K, Kay J, Walensky RP, Mullins ME, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. N Engl J Med. 2006 Dec 21; 355(25):2678-89. PMID: 17182994.
      Citations: 1     Fields:    Translation:HumansAnimals
    118. Sarraf P, Kay J, Friday RP, Reginato AM. Wegener's granulomatosis: is biologic therapy useful? Curr Rheumatol Rep. 2006 Aug; 8(4):303-11. PMID: 16839510.
      Citations: 3     Fields:    Translation:HumansAnimals
    119. Kay J, Finn DS, Stone JR. Case records of the Massachusetts General Hospital. Case 4-2006. A 79-year-old woman with myalgias, fatigue, and shortness of breath. N Engl J Med. 2006 Feb 09; 354(6):623-30. PMID: 16467550.
      Citations: 3     Fields:    Translation:Humans
    120. Kay J, McCluskey RT. Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency. N Engl J Med. 2005 Oct 13; 353(15):1605-13. PMID: 16221784.
      Citations: 2     Fields:    Translation:Humans
    121. Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med. 2004 Nov 18; 351(21):2219-27. PMID: 15548783.
      Citations: 9     Fields:    Translation:Humans
    122. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2004 Jun; 43 Suppl 3:iii2-iii9. PMID: 15150426.
      Citations: 85     Fields:    Translation:HumansAnimalsCells
    123. Saudek DM, Kay J. Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep. 2003 Feb; 5(1):33-40. PMID: 12590883.
      Citations: 21     Fields:    Translation:Humans
    124. Casato M, Mecucci C, Agnello V, Fiorilli M, Knight GB, Matteucci C, Gao L, Kay J. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood. 2002 Mar 15; 99(6):2259-61. PMID: 11877309.
      Citations: 15     Fields:    Translation:HumansCells
    125. Hou FF, Miyata T, Boyce J, Yuan Q, Chertow GM, Kay J, Schmidt AM, Owen WF. beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int. 2001 Mar; 59(3):990-1002. PMID: 11231354.
      Citations: 20     Fields:    Translation:HumansCells
    126. Salahuddin N, Libman BS, Lunde JH, Kay J, Cooper SM. The association of relapsing polychondritis and myelodysplastic syndrome: report of three cases. J Clin Rheumatol. 2000 Jun; 6(3):146-9. PMID: 19078463.
      Citations: 1     Fields:    
    127. Kay J, Bardin T. Osteoarticular disorders of renal origin: disease-related and iatrogenic. Baillieres Best Pract Res Clin Rheumatol. 2000 Jun; 14(2):285-305. PMID: 10925746.
      Citations: 3     Fields:    Translation:Humans
    128. Kay J. Beta 2-microglobulin amyloidosis in renal failure: understanding this recently recognized condition. Cleve Clin J Med. 1999 Mar; 66(3):145-7. PMID: 10079583.
      Citations: 4     Fields:    Translation:Humans
    129. Jimenez RE, Price DA, Pinkus GS, Owen WF, Lazarus JM, Kay J, Turner JR. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol. 1998 Jun; 22(6):729-35. PMID: 9630180.
      Citations: 5     Fields:    Translation:Humans
    130. Owen WF, Hou FF, Stuart RO, Kay J, Boyce J, Chertow GM, Schmidt AM. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 1998 May; 53(5):1365-73. PMID: 9573554.
      Citations: 13     Fields:    Translation:HumansCells
    131. Hou FF, Boyce J, Chertow GM, Kay J, Owen WF. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol. 1998 Feb; 9(2):277-83. PMID: 9527404.
      Citations: 5     Fields:    Translation:HumansCells
    132. Hou FF, Chertow GM, Kay J, Boyce J, Lazarus JM, Braatz JA, Owen WF. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int. 1997 May; 51(5):1514-9. PMID: 9150467.
      Citations: 9     Fields:    Translation:HumansCells
    133. Chertow GM, Trimbur T, Karlson EW, Lazarus JM, Kay J. Performance characteristics of a dialysis-related amyloidosis questionnaire. J Am Soc Nephrol. 1996 Aug; 7(8):1235-40. PMID: 8866418.
      Citations: 1     Fields:    Translation:Humans
    134. Berarducci M, Thomas C, Kay J. Churg-strauss syndrome with diffuse gastrointestinal involvement. J Clin Rheumatol. 1996 Aug; 2(4):221-6. PMID: 19078069.
      Citations: 2     Fields:    
    135. Grevelink S, Moschella SL, Kay J. Dermatomyositis update. J Clin Rheumatol. 1995 Feb; 1(1):2-12. PMID: 19077934.
      Citations: 1     Fields:    
    136. Kay J, Czop JK. Enhancement of human monocyte beta-glucan receptors by glucocorticoids. Immunology. 1994 Jan; 81(1):96-102. PMID: 8132226.
      Citations: 2     Fields:    Translation:HumansCells
    137. Kay J, Preibisz JM. Lyme disease. Compr Ther. 1993; 19(4):157-62. PMID: 8261770.
      Citations:    Fields:    Translation:Humans
    138. Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum. 1992 Aug; 35(8):926-32. PMID: 1642657.
      Citations: 6     Fields:    Translation:Humans
    139. Gravallese EM, Baker N, Lester S, Kay J, Owen WF. Musculoskeletal manifestations in beta 2-microglobulin amyloidosis. Case discussion. Arthritis Rheum. 1992 May; 35(5):592-602. PMID: 1575795.
      Citations: 3     Fields:    Translation:Humans
    140. Czop JK, Kay J. Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. J Exp Med. 1991 Jun 01; 173(6):1511-20. PMID: 1851799.
      Citations: 18     Fields:    Translation:HumansCells
    141. Kay J, Austen KF, Czop JK. Identification and characterization of opsonic fibronectin in synovial fluids of patients with active rheumatoid arthritis. Arthritis Rheum. 1991 Jun; 34(6):687-96. PMID: 1711322.
      Citations: 2     Fields:    Translation:HumansCells
    142. Matsuyama T, Yamada A, Kay J, Yamada KM, Akiyama SK, Schlossman SF, Morimoto C. Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. J Exp Med. 1989 Oct 01; 170(4):1133-48. PMID: 2477485.
      Citations: 76     Fields:    Translation:HumansCells
    143. Kay J, Eichenfield AH, Athreya BH, Doughty RA, Schumacher HR. Synovial fluid eosinophilia in Lyme disease. Arthritis Rheum. 1988 Nov; 31(11):1384-9. PMID: 3056421.
      Citations: 1     Fields:    Translation:HumansCells
    144. Kay J, Stricker RB. Hematologic and immunologic abnormalities in anorexia nervosa. South Med J. 1983 Aug; 76(8):1008-10. PMID: 6348960.
      Citations: 4     Fields:    Translation:HumansCells
    145. Lee KC, Kay J, Wong M. Separation of functionally distinct subpopulations of Corynebacterium parvum-activated macrophages with predominantly stimulatory or suppressive effect on the cell-mediated cytotoxic T cell response. Cell Immunol. 1979 Jan; 42(1):28-41. PMID: 312146.
      Citations: 7     Fields:    Translation:AnimalsCells
    Kay's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (503)
    Explore
    _
    Co-Authors (11)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _